Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells

被引:15
作者
Andrews, J [1 ]
Abd-Ellah, MF
Randolph, NL
Kenworthy, KE
Carlile, DJ
Friedberg, T
Houstont, JB
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
关键词
D O I
10.1080/00498250210163289
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The aim was to compare the metabolic activity of human CYP3A4 expressed in bacteria (E. coli), yeast (S. cerevisiae) and human lymphoblastoid cells (hBl), with the native CYP3A4 activity observed in a panel of human livers. 2. Three CYP3A4 substrates were selected for study: dextromethorphan (DEM), midazolam (MDZ) and diazepam (DZ). The substrate metabolism in each of the four systems was characterized by deriving the kinetic parameters K-m or S-50, V-max and intrinsic clearance (CLint) or maximum clearance (CLmax) from the kinetic profiles; the latter differing by 100-fold across the three substrates. 3. The K-m or S-50 for the formation of metabolites 3-methoxymorphinan (MEM), 1'-hydroxymidazolam (1'-OH MDZ) and 3-hydroxydiazepam (3HDZ) compared well in all systems. For CYP3A4-mediated metabolism of DEM, MDZ and DZ, the V-max for hBl microsomes were generally 2-9-fold higher than the respective yeast and human liver microsomes and E. coli membrane preparations, resulting in greater CLint or CLmax. In the case of 3HDZ formation, non-linear kinetics were observed for E. coli, hBl microsomes and human liver microsomes, whereas the kinetics observed for S. cerevisiae were linear. 4. The use of native human liver microsomes for drug metabolic studies will always be preferable. However, owing to the limited availability of human tissues, we find it is reasonable to use any of the recombinant systems described herein, since all three recombinant systems gave good predictions of the native human liver enzyme activities.
引用
收藏
页码:937 / 947
页数:11
相关论文
共 38 条
[1]   PHARMACOLOGY OF DORMICUM (MIDAZOLAM) AND ANEXATE (FLUMAZENIL) [J].
AMREIN, R ;
HETZEL, W .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1990, 34 :6-15
[2]   DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) :131-137
[3]  
ASHFORTH EIL, 1995, J PHARMACOL EXP THER, V274, P761
[4]   Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli [J].
Blake, JAR ;
Pritchard, M ;
Ding, SH ;
Smith, GCM ;
Burchell, B ;
Wolf, CR ;
Friedberg, T .
FEBS LETTERS, 1996, 397 (2-3) :210-214
[5]   SIMULTANEOUS DETERMINATION OF DEXTROMETHORPHAN AND 3 METABOLITES IN PLASMA AND URINE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH APPLICATION TO THEIR DISPOSITION IN MAN [J].
CHEN, ZR ;
SOMOGYI, AA ;
BOCHNER, F .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :97-104
[6]  
Crespi C L, 1997, Adv Pharmacol, V43, P171, DOI 10.1016/S1054-3589(08)60205-7
[7]  
Crespi CL., 1995, Advances in drug research, V26, P179, DOI DOI 10.1016/S0065-2490(05)80006-1
[8]   Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity [J].
Ducharme, J ;
Abdullah, S ;
Wainer, IW .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (01) :113-128
[9]   Recombinant DNA technology as an investigative tool in drug metabolism research [J].
Friedberg, T ;
Wolf, CR .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) :187-213
[10]  
Ghosal A, 1996, DRUG METAB DISPOS, V24, P940